Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Intellect Neurosciences, Inc. (OTC: ILNS).

Full DD Report for ILNS

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-03N/A0.001N/AN/A0
2018-11-30N/A0.001N/AN/A0
2018-11-290.00110.0010.00110.00115,040
2018-11-280.0010.0010.0010.001881
2018-11-27N/A0.001N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-09-1485201.5385Cover
2018-08-275,36518,99628.2428Cover
2018-08-211,50025,5005.8824Cover
2018-08-1310,00010,40096.1538Short
2018-08-10224450.0000Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ILNS.


About Intellect Neurosciences, Inc. (OTC: ILNS)

Logo for Intellect Neurosciences, Inc. (OTC: ILNS)

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions. The company s internal drug discovery programs are focused on the therapeutic applications of monoclonal antibodies and antibody drug conjugates. Intellect has granted licenses to global pharmaceutical companies covering several of the patents in its intellectual property portfolio, which will entitle the company to significant milestone payments and sales based royalties upon successful development and commercialization of the licensed drug candidates.

 

Contact Information

 

 

Current Management

  • Elliot M. Maza / CEO, CFO
    • Mr. Maza has served as our Chief Executive Officer, Chief Financial Officer and chairman of the Board of Directors since July . Mr. Maza joined the Company in May as Chief Financial Officer and was promoted to President and Chief Financial Officer in March . From December to May , Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a publicly held biopharmaceutical company specializing in oral drug delivery. He was a partner at Ernst and Young LLP from March to December and served as a Vice President at Goldman Sachs, Inc. and JP Morgan Securities, Inc. at various times during March to March . Mr. Maza began his career as an attorney at Sullivan amp Cromwell, LLP.
  • Elliot M. Maza / Chairman
    • Mr. Maza has served as our Chief Executive Officer, Chief Financial Officer and chairman of the Board of Directors since July . Mr. Maza joined the Company in May as Chief Financial Officer and was promoted to President and Chief Financial Officer in March . From December to May , Mr. Maza was Chief Financial Officer of Emisphere Technologies, Inc., a publicly held biopharmaceutical company specializing in oral drug delivery. He was a partner at Ernst and Young LLP from March to December and served as a Vice President at Goldman Sachs, Inc. and JP Morgan Securities, Inc. at various times during March to March . Mr. Maza began his career as an attorney at Sullivan amp Cromwell, LLP.
  • Isaac Onn / Independent Director
    • Mr. Onn has served as a member of our Board of Directors since . Mr. Onn serves as a director on the boards of several private and public companies across diverse industry sectors. Mr. Onn served as the Chief Executive Officer of Erez Tal Bar Fueling Services Ltd., an Israeli company that builds and manages fuel stations. Mr. Onn received his degree in business administration and marketing from the TelAviv College of Management and his LLB, Bachelor of Law degree from Ono Academic College Law School in Israel.

Current Share Structure

  • Market Cap: $267,336 - 03/15/2018
  • Authorized: 2,000,000,000 - 11/04/2015
  • Issue and Outstanding: 6,520,389 - 05/09/2016
  • Float: 4,717,663 - 11/04/2015

 


Recent Filings from (OTC: ILNS)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (OTC: ILNS)

Daily Technical Chart for (OTC: ILNS)


Stay tuned for daily updates and more on (OTC: ILNS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ILNS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ILNS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ILNS and does not buy, sell, or trade any shares of ILNS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/